Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Depreciation & Amortization (CF) (2018 - 2025)

Viemed Healthcare's Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $7.6 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 18.91% year-over-year to $7.6 million; the TTM value through Dec 2025 reached $28.6 million, up 12.79%, while the annual FY2025 figure was $28.6 million, 12.79% up from the prior year.
  • Depreciation & Amortization (CF) reached $7.6 million in Q4 2025 per VMD's latest filing, roughly flat from $7.5 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $7.6 million in Q4 2025 to a low of $2.6 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $5.1 million, with a median of $5.6 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 44.99% in 2023, then rose 5.22% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.1 million in 2021, then soared by 40.16% to $4.4 million in 2022, then surged by 35.35% to $5.9 million in 2023, then increased by 7.55% to $6.4 million in 2024, then grew by 18.91% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for VMD's Depreciation & Amortization (CF) are $7.6 million (Q4 2025), $7.5 million (Q3 2025), and $6.9 million (Q2 2025).